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Background. The aim of the study was to analyze the clinical and imaging characteristics of primary intrathoracic 
malignant peripheral nerve sheath tumors (MPNSTs). 
Patients and methods. In this institutional review board (IRB)-approved retrospective study, clinical and imaging 
features of 15 patients (eight men; mean age 50 years [range 18–83)] with pathologically proven malignant peripheral 
nerve sheath tumors seen from January 1999 to December 2011 were analyzed. Imaging features (CT in 15, MRI in 5 
and PET/CT in 4) of primary tumors were evaluated by three radiologists and correlated with clinical management. 
Results. Of the 15 tumors, six were located in the mediastinum (two each in anterior, middle and posterior mediasti-
num), four in chest wall, two were paraspinal, and three in the lung. Four patients had neurofibromatosis-1 (NF1); four 
tumors had heterologous rhabdomyoblastic differentiation (malignant triton tumor). Masses typically were elongated 
along the direction of nerves, with mean size of 11 cm. The masses were hypo- or isodense to muscles on CT, isointense 
on T1-weighted images, hyperintense on T2-weighted images and intensely fluorodeoxyglucose (FDG) avid (mean 
standardized uptake value [SUV]max of 10.5 [range 4.4–23.6]). Necrosis and calcification was seen in four tumors each. 
Finding of invasion of adjacent structures on imaging led to change in management in seven patients; patients with 
invasion received chemoradiation. 
Conclusions. Intrathoracic MPNSTs appear as large elongated masses involving mediastinum, lung or chest wall. 
Radiological identification of invasion of adjacent structures is crucial and alters therapy, with patients with invasion 
receiving neoadjuvant or adjuvant chemoradiation.
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Introduction
Malignant peripheral nerve sheath tumors 
(MPNSTs) are rare, accounting for 5-10% of all soft 
tissue sarcomas.1 MPNSTs usually demonstrate 
nerve sheath differentiation, and although they 
grossly appear similar to benign peripheral nerve 
sheath tumors such as schwannomas and neurofi-
bromas, MPNSTs commonly contain hyperchro-
matic spindle cells with nuclear atypia, mitotic ac-
tivity, and areas of tumor necrosis on histology.1,2 
Rapid enlargement, pain, or associated neurologi-
cal symptoms favor MPNST over a benign nerve 
sheath tumor.1 MPNSTs are most often sporadic, Radiol Oncol 2013; 47(3): 230-238.
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cle) differentiation are called malignant triton tu-
mors (MTTs). MPNSTs have an aggressive clinical 
course with 5- and 10-year survival rates of 34–60% 
and 22–45% respectively.1,5 MTT is associated with 
an even worse clinical outcome, with a 5-year sur-
vival rate of 11–15%.6 Location also plays a role in 
outcome, with tumors in the trunk associated with 
poorer prognosis, likely attributable to difficulty 
in achieving negative surgical margins and conse-
quent local or regional recurrence.1,5 While study-
ing the impact of rhabdomyoblastic differentiation 
(MTT), presence of NF1 and location on the out-
although 20–30% occur in association with neu-
rofibromatosis-1 (NF1).1 Patients typically present 
around age 40–501, although patients with NF1 of-
ten present earlier (mean age 30 years).3 MPNSTs 
most often occur in the extremities1, followed by 
trunk and head and neck, however MPNSTs can 
arise anywhere in the body. Intrathoracic MPNST 
are particularly rare.4 Pathologically, MPNSTs 
typically have a fascicular growth pattern and 
are composed of spindle cells with variable nu-
clear atypia and mitotic activity. MPNSTs with 
heterologous rhabdomyoblastic (i.e. skeletal mus-
FIGURE 1. A 31-year-old man with mediastinal malignant 
peripheral nerve sheath tumor. A.  Axial contrast-enhanced 
CT (CECT) shows a low attenuating mildly enhancing posterior 
mediastinal mass (arrow) displacing the aorta, azygous 
vein and esophagus. The mass encompasses more than 
50% circumference of the descending thoracic aorta.   
B.  Coronal T2-weighted MR image shows a heterogeneous 
lobulated hyperintense mass (arrow). C. Coronal maximum 
intensity projection (MIP) PET image shows a moderately 
fluorodeoxyglucose (FDG) avid mediastinal mass (arrow, 
standardized uptake value [SUV]max 5.2). Physiologic activity is 
noted in the heart (arrowhead).
A
B
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come of 84 consecutive patients with MPNST7, we 
noticed that the imaging literature on intrathoracic 
MPNST is extremely limited, consisting mostly 
of case reports with little information on imaging 
findings.4,8–14 Therefore, the purpose of this study 
was to assess the clinical and imaging characteris-
tics of primary intrathoracic MPNST.
Patients and methods
Patients
In this institutional review board-approved study, 
the electronic pathology patient database was re-
viewed to identify patients with pathologically 
proven primary intrathoracic MPNSTs (mediasti-
num, lung, and chest wall tumors) evaluated at our 
institution from January 1999 to December 2011. 
First, we identified a total of 110 patients with 
pathologically proven MPNSTs. Among them, 26 
patients were excluded because they were referred 
from outside institution and the pathology of the 
primary tumor was not confirmed by review at 
our institution. Among the remaining 84 patients, 
21 patients had intrathoracic MPNSTs. Of these 
21 patients, 6 were excluded because imaging of 
the primary tumor was not available. Therefore, 
the final study population consisted of 15 patients 
with pathologically proven intrathoracic MPNST 
who had imaging of primary tumors available for 
review. Mediastinal tumor localization was de-
termined by an adaptation of the Felson method-
ology. For large tumors, we used the epicenter of 
the tumor to define its location. Clinical features 
including clinical presentation and treatment were 
correlated with imaging findings.
Image Analysis
All imaging analysis was performed, in consensus, 
by three radiologists (N.R., S.H. and A.S.) with 13, 
10 and 7 years of experience. Images were reviewed 
on the picture archiving and communication sys-
tem (PACS) using commercially available worksta-
tions (Centricity, General Electric, Barrington, IL). 
A systematic review of available imaging stud-
ies was performed and location, size (single longest 
dimension was selected by manually placing cali-
per on the axial or coronal images), and imaging 
features (CT in 15, MRI in 5 and PET/CT in 4) of 
the primary tumors were recorded. CT attenuation 
of the tumor was compared to muscles by plac-
ing a circular region of interest (ROI) in the most 
representative portion of the tumor. Image inten-
A
B
FIGURE 2. A 67-year-old man with MPNST involving the left lung. A. Unenhanced 
CT image of the chest at the level of main pulmonary arteries shows a lobulated 
mass abutting the left hilum with peripheral foci of calcification (arrow).   
B. Coronal maximum intensity projection (MIP) image from PET/CT shows an intensely 
fluorodeoxyglucose (FDG) avid mass (arrow, standardized uptake value [SUV]max 
23.6). Patient underwent left pneumonectomy on which intrapulmonary location of 
the mass was confirmed. Rhabdomyoblastic differentiation (malignant triton tumor) 
was noted on pathology.Radiol Oncol 2013; 47(3): 230-238.
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sity on T1 and T2-weighted images was visually 
compared to muscles. Degree of enhancement was 
evaluated in comparison with skeletal muscle and 
graded as mild if less enhancement than skeletal 
muscle, moderate if similar degree of enhancement 
as muscle (considered similar for the purpose of 
this study if the ROI values were within 10% the 
muscle), and intense if more enhancement than 
muscle using ROI measurements, similar to previ-
ous reports.15 Homogeneous or heterogeneous ap-
pearance of the tumors on CT and MRI, presence of 
hemorrhage (defined as areas that are hyperdense 
on unenhanced CT images or T1-hyperintense ar-
eas on T1-weighted MR images), necrosis (defined 
as hypodense and/or T2-hyperintense, non-en-
hancing area within the tumor), and calcifications 
were also recorded. Degree of fluorodeoxyglucose 
(FDG) uptake was measured on PET/CT images 
by manually placing a circular ROI over the most 
FDG avid portion of the lesion on a commercially 
available workstation (Hermes, Hermes Medical 
Solutions Inc, Greenville, NC, USA). Standardized 
uptake value (SUV)max was used to represent the 
FDG uptake of the tumor. Invasion of adjacent 
structures, seen as extension of tumor invading 
and distorting the adjacent tissues, was noted and 
its impact on management was studied. 
Differentiation between malignant and benign 
nerve sheath tumors is challenging, especially in 
NF1 patients. Signs of malignancy in this context 
on imaging include high attenuation and necrosis/
hemorrhage on CT, heterogeneity on T1 weighted 
images in MR, and rapidly increasing size.16,17
Results
Patients
Among 15 eligible patients, there were eight men 
and seven women (Table 1). The average age at di-
agnosis was 49 years (range: 18–83 years). Eleven 
patients had conventional MPNSTs, and 4 patients 
had MTT (27%). The average age of the MPNST 
patients was 50 (range 18–83) while the average 
age of the MTT patients was 40 (range 27–67). Four 
patients (27%) had NF1 (2 patients with MPNST, 2 
patients with MTT).
Six tumors (40%) were located in the mediasti-
num (two anterior, two middle and two in poste-
rior mediastinum) (Figure 1), four (27%) were in 
the chest wall (Figure 2), three (20%) involved the 
lung, and two were paraspinal (13%) (Figure 3). 
Of the six mediastinal tumors, all were conven-
tional MPNSTs and 2 were associated with NF1 
(33%). Of the four chest wall tumors, 2 were MTT, 
both of which were associated with NF1 (50%), 
while the other two were conventional sporadic 
MNPST. Of the three lung tumors, 1 was a MTT 
(33%); none of these patients had NF1. Of the two 
paraspinal tumors, 1 was a MTT (50%) and none of 
the patients had NF1.
Nine patients presented with a chief complaint 
of pain, three with back pain, three with pleurit-
ic chest pain, two with painful chest wall lumps, 
and one with right arm pain. Six patients present-
ed with dyspnea or respiratory distress. One pa-
tient presented with right arm tingling/swelling. 
Table 2 summarizes the clinical presentation of the 
patients with intrathoracic MPNST. Only one pa-
tient was asymptomatic, with a large subxiphoid 
mass detected on surveillance imaging; the pa-
tient had received chemotherapy and radiation for 
Hodgkin’s lymphoma 14 years prior to developing 
an MPNST. Clinical information regarding presen-
tation was unavailable for one patient. 
Imaging features of primary tumors
All patients had a single tumor representing 
MPNST. Average tumor size was 11 cm (range 3–32 
cm) (Table 3). Patients with MTT tended to have 
larger tumors at diagnosis (mean size 15 cm) than 
those with conventional MPNSTs (mean size 9 cm). 
However, this difference could not be statistically 
assessed due to a small sample size. 
On CT, eight tumors (53%) had lower attenua-
tion than muscle and seven (47%) were isoattenu-
ating. On MRI, all five masses were isointense to 
muscles on T1-weighted images and hyperintense 
on T2-weighted images. Ten masses demonstrated 
mild enhancement, four had moderate enhance-
ment, and one patient only had unenhanced CT. 
Eight (53%) masses were heterogeneous and seven 
(47%) were homogeneous. 
Calcifications were seen in four lesions (27%) 
and four (27%) had features suggestive of necrosis. 
Three patients had punctate calcifications and one 
had chunky, nodular calcifications; calcifications 
were peripheral in two patients, central in one pa-
tient, and diffusely scattered in one. Of the four 
masses with appearance suggestive of necrosis on 
imaging, two had necrosis on pathology and one 
had cystic degeneration. No necrosis or cystic de-
generation was noted on pathology in the fourth 
patient. Hemorrhage was seen in two masses 
(13%). 
The four masses that underwent PET/CT were 
intensely FDG––avid with mean SUVmax of 10.5 Radiol Oncol 2013; 47(3): 230-238.
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(range 4.4–23.6). One of these had MTT, and we 
noticed that this tumor had higher SUVmax (23.6) 
than those without MTT (mean 6.1, range 4.4–8.9). 
Again, this difference could not be statistically ana-
lyzed given the small number of patients with this 
rare entity.
Neuroforaminal extension was seen in one pos-
terior mediastinum patient and one paraspinal 
patient. Two patients had evidence of rib erosion 
on imaging, while two patients had evidence of 
rib displacement. Of the six mediastinal cases, four 
had invasion or encasement of adjacent structures 
on imaging such as trachea, mediastinal great ves-
sels and esophagus, and one had intraspinal exten-
sion. Of the chest wall cases, one had invasion of 
adjacent tissues (4 cm) and another large mass had 
extensive invasion and displacement of multiple 
adjacent structures. All three of the lung cases had 
invasion of nearby structures including chest wall, 
diaphragm and mediastinum. Of the paraspinal 
cases, one patient presented with lung metastases, 
and the other patient had invasion into paraspinal 
musculature and extrapleural fat.
Management
In general, surgery was the treatment of choice 
whenever possible. Large masses which were ini-
tially deemed unresectable received neoadjuvant 
chemotherapy or chemoradiation, following which 
they were surgically resected if there was response 
and if they were considered resectable. Patients 
with nonradical resection received adjuvant chem-
otherapy. 
Two posterior mediastinal masses and one mid-
dle mediastinal mass were treated with neoadju-
vant chemoradiation or chemotherapy followed 
by surgery. The patient with the 14cm posterior 
mediastinal mass received concurrent chemother-
apy (etoposide/ifosfamide) and radiation followed 
by surgical resection, as the tumor was initially 
deemed unresectable. One patient with middle 
mediastinal mass and another with an anterior me-
diastinal mass underwent chemoradiation alone as 
they were deemed unresectable. The patient with 
the anterior mediastinal mass received chemo-
therapy (etoposide/cisplatin) followed by radia-
tion, the patient with the middle mediastinal mass 
received concurrent chemotherapy (adriamycin/
ifosfamide) and radiation. Another patient with a 
4 cm subxiphoid mass was resected without neo-
adjuvant therapy.
Of the four patients with chest wall masses, the 
4 cm invasive mass and another large mass (17 cm) 
underwent surgery and chemoradiation, and one 
small mass (3 cm) was treated with surgical re-
section. The patient with the 4 cm invasive mass 
initially underwent non-radical resection, followed 
TABLE 1. Clinical features of patients with malignant peripheral nerve sheath tumor (MPNST) of chest
Sr 
No Age Sex NF1 Location Size (cm) Histology (MPNST/MTT) Management
1 38 F Yes Middle mediastinum 16 MPNST Chemoradiation
2 31 M No Posterior mediastinum 14 MPNST Neoadjuvant chemoradiation,  
followed by surgery
3 48 M No Anterior mediastinum 13.6 MPNST Chemoradiation
4 18 F Yes Middle mediastinum 8 MPNST Neoadjuvant chemoradiation,  
followed by surgery
5 65 M No Posterior mediastinum 5.5 MPNST Neoadjuvant chemotherapy and surgery
6 33 F No Anterior mediastinum-
subxiphoid 4 MPNST Surgery
7 83 F No Chest wall 17 MPNST Surgery, followed by chemoradiation
8 60 M No Chest wall 3 MPNST Surgery
9 27 M Yes Chest wall 4 MTT Surgery, followed by chemoradiation
10 44 F Yes Chest wall 32 MTT None
11 51 F No Left lung 4.5 MPNST Neoadjuvant chemotherapy and surgery
12 63 M No Left lung unknown MPNST Chemotherapy
13 67 M No Left lung 12.8 MTT Surgery
14 58 M No Paraspinal 2.5 MPNST Chemoradiation
15 61 F No Paraspinal 10 MTT ChemotherapyRadiol Oncol 2013; 47(3): 230-238.
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by radiation therapy, re-resection, and then chem-
otherapy with vincristine/actinomycin/cyclophos-
phamide/mesna; exact details of chemotherapy 
were not available for the 17cm chest wall mass as 
patient received chemotherapy at an outside insti-
tution. The one patient with the 32 cm mass and 
extensive invasion of adjacent structures died prior 
to any treatment. 
Of the three lung tumors, one case with me-
diastinal invasion was treated with neoadjuvant 
chemotherapy followed by surgery, one case with 
a chest wall and diaphragmatic invasion was treat-
ed with chemotherapy, and a hilar mass with inva-
sion of the pulmonary artery was treated with total 
pneumonectomy. 
Of the two paraspinal cases, one patient was 
treated with chemoradiation (further details not 
available), while the other was treated with chemo-
therapy alone, as the patient presented initially 
with widespread metastatic disease.
Discussion
Thoracic MPNSTs may involve mediastinum, lung 
or chest wall, with those in the mediastinum or 
chest wall manifesting as large elongated masses. 
They are often heterogeneous on CT and MRI, and 
intensely FDG-avid on PET. To our knowledge, 
this is the largest study of imaging findings of in-
trathoracic MPNST.
MPNSTs are rare, aggressive soft tissue sarco-
mas occurring anywhere in the body. They often 
occur in association with NF1, with an incidence 
ranging from 20–30%.1,3,5 Four patients in our study 
had NF1 (27%); this number is consistent with the 
reported incidence. MPNSTs most commonly oc-
cur in the extremities; intrathoracic MPNST are 
rarely reported, mostly in the form of isolated case 
reports. If MPNSTs arise in the nerves of the deep 
tissue, as occurs frequently with thoracic tumors, 
early diagnosis is clinically more difficult.4 Pain 
was the most common complaint and presenting 
symptom in others (7/15 patients). In a recent series 
of 175 patients with MPNSTs conducted at Mayo 
Clinic, the median tumor size was 6.0 cm1; our av-
erage tumor size was 11 cm.
MTT, defined by the presence of rhabdomyo-
blasts in an MPNST on pathology, account for < 
10% of MPNSTs.6 MTTs behave more aggressively 
than conventional MPNSTs. Out of the 15 patients 
in our study, 4 had the MTT subtype (27%). These 
patients had a larger tumor size at diagnosis, meas-
uring 15 cm compared to 9 cm for conventional 
MPNSTs. 
MPNSTs typically are ovoid, occurring along a 
nerve18, and presenting as a non-specific soft tis-
sue mass. MPNSTs have low attenuation on CT.9 
TABLE 2. Initial presentation of patients with malignant peripheral nerve sheath tumor (MPNST) of the chest
Sr 
No Location Size (cm) Histology (MPNST/MTT) Presentation
1 Middle mediastinum 16 MPNST Right arm pain with radiation to axilla
2 Posterior mediastinum 14 MPNST Back pain
3 Anterior mediastinum 13.6 MPNST Dyspnea, found to have mass with partial obstruction 
of right mainstem bronchus
4 Middle mediastinum 8 MPNST Dyspnea/pleuritic chest pain and pleural effusion
5 Posterior mediastinum 5.5 MPNST Back pain
6 Anterior mediastinum-subxiphoid 4 MPNST Asymptomatic, found on routine screening
7 Chest wall 17 MPNST Right arm tingling/swelling
8 Chest wall 3 MPNST Painful chest wall lump
9 Chest wall 4 MTT Painful chest wall lump
10 Chest wall 32 MTT Dyspnea/pleuritic chest pain and pleural effusion
11 Left lung 4.5 MPNST PNA, tx’d, with continuing decline  
and respiratory distress
12 Left lung unknown MPNST Dyspnea/pleuritic chest pain and pleural effusion
13 Left lung 12.8 MTT Unknown
14 Paraspinal 2.5 MPNST Back pain
15 Paraspinal 10 MTT Lung mets and dyspnea on exertion
MTT = malignant triton tumors; Sr No = serial numberRadiol Oncol 2013; 47(3): 230-238.
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On MR, MPNSTs are isointense on T1 and hyperin-
tense on T2.8 Our findings for intrathoracic MPNST 
are similar, as 8/15 patients had hypoattenuating 
lesions on CT, and of the five patients with MR, all 
had isointense lesions on T1 and hyperintense le-
sions on T2. MPNSTs present as FDG-avid masses 
and can therefore be evaluated using PET/CT.19 
Differentiation between malignant and benign 
nerve sheath tumors is challenging, especially in 
NF1 patients. Signs of MPNST on imaging include 
high attenuation and necrosis/hemorrhage on 
CT, heterogeneity on T1 weighted images in MR, 
and rapidly increasing size.16,17 A “target sign”, or 
a central hypodense region on T2-weighted im-
FIGURE 3. A 60-year-old man with left chest wall MPNST. A. Axial unenhanced CT 
image shows a low attenuation right chest wall mass abutting a rib (arrow) causing 
rib destruction and adjacent pleural thickening. B. Axial fused PET/CT image shows 
presence of moderate fluorodeoxyglucose (FDG) uptake (arrow, standardized 
uptake value [SUV]max 4.4).
A
B
ages, was previously implicated as an indicator 
for MPNST, but this has not been corroborated by 
other groups.2,20,21 Our data also did not confirm 
this finding, as a target sign was only seen in one 
patient. MPNST should be considered in the differ-
ential diagnosis for large thoracic masses found on 
imaging, especially if they are located along major 
nerves. MPNST should be especially high on the 
differential diagnosis if a thoracic mass is found in 
a patient with NF1. 
Treatment of MPNST relies primarily on sur-
gical resection.4 Neoadjuvant chemoradiation is 
often used for initially unresectable tumors with 
an intention to downstage the mass pre-resec-
tion. Radiation therapy can be given in addition 
to surgical resection for improved local control.5 
Chemotherapy is typically reserved for aggressive 
cases, and also when there is tumor rupture, posi-
tive margins, or metastases, although improve-
ment in survival has not been demonstrated.1 In 
an analysis of MPNST patients who received either 
surgery alone or multimodality treatment, the rate 
of recurrence was not significantly affected7, how-
ever, given the aggressive nature of MPNSTs, mul-
timodality treatment is typically recommended. 
To the best of our knowledge, there are no studies 
comparing the efficacy of sequential versus concur-
rent chemoradiation in the treatment of MPNSTs.
Imaging assists with management of these pa-
tients, as tumors visualized to have invasion or 
compression of nearby structures often undergo 
additional therapy prior to surgical resection. PET/
CT may play an important role in MPNST manage-
ment, as increased FDG uptake is associated with 
malignant transformation, and PET/CT has 72% 
specificity for diagnosis of malignancy.19 In addi-
tion, whole-body MRI adequately assesses tumor 
burden in patients with NF1, and can allow visuali-
zation of tumors not observed on physical exami-
nation. This technique allows close surveillance of 
neurofibromas in NF1 patients and may allow for 
earlier detection of malignant transformation.21,23 
An important limitation to this study was small 
sample size. However, intrathoracic MPNST are 
rare, and there are no prior reports on imaging fea-
tures of series of these tumors. Due to the retro-
spective nature of the study with patients undergo-
ing imaging evaluation as clinically indicated, we 
do not have MRI or PET/CTs for all 15 patients. As 
these are rare tumors, there is no fixed protocol for 
imaging evaluation of these masses. 
In summary, intrathoracic MPNST may in-
volve the mediastinum, lung and chest wall; me-
diastinal and chest wall tumors are usually large Radiol Oncol 2013; 47(3): 230-238.
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elongated masses along the course of nerves. They 
are usually hypoattenuating on CT, hyperintense 
on T2-weighted images, are often heterogeneous, 
and are intensely FDG-avid masses. Comparison 
with previously published data on MPNSTs sug-
gests that intrathoracic MPNST are similar in ap-
pearance to MPNSTs in other locations, but these 
tumors may present larger in size. For MPNSTs, 
imaging is often nonspecific, and although we as 
radiologists can raise the possibility, an accurate 
diagnosis always needs histologic confirmation. 
MPNST should be considered in the differential di-
agnosis when a large, elongated intrathoracic mass 
is found. The role of the radiologist lies in identifi-
cation of invasion of adjacent structures as patients 
with invasion receive neoadjuvant or adjuvant 
chemoradiation.
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